INVESTALGA AHTI S.L.

INVESTALGA is a Spanish innovative biotech specializing in the production of high quality bioactive compounds from green seaweeds available for use in nutrition, personal care and health markets. We are developing a scientific-technical-industrial base combining various disciplines: biotechnology, marine ecology, aquaculture, chemistry, nutrition and medicine, to credit and put value to the numerous possibilities derived from the unique biochemical composition of green seaweeds.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DECK 7 OPTIMIZES ITS STRATEGIC MARKETING FOR 2020 USING A REVISED ABM STRATEGY

PR.com | February 04, 2020

news image

Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. Th...

Read More

CELL AND GENE THERAPY

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

news image

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More

OBSIDIAN THERAPEUTICS ANNOUNCES BRISTOL MYERS SQUIBB OPT-IN OF CYTODRIVE™ CELL THERAPY CANDIDATE

Obsidian Therapeutics | September 16, 2020

news image

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop nov...

Read More

ENTERPRISE THERAPEUTICS NABS NOVARTIS VC EXEC AS NEW CMO

FierceBiotech | February 10, 2020

news image

Britain-based biotech Enterprise Therapeutics has hired Novartis Venture Fund managing director David Morris, M.D., as its next chief medical officer. Morris, who will continue to serve as the fund’s operating partner, will lead Enterprise’s development strategy and drive its two lead respiratory programs through the clinic. These are ETD002, a first-in-class TMEM16A potentiator, and ETD001, an ENaC blocker, both of which are hoping to help cystic fibrosis (CF) patients....

Read More
news image

DECK 7 OPTIMIZES ITS STRATEGIC MARKETING FOR 2020 USING A REVISED ABM STRATEGY

PR.com | February 04, 2020

Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. Th...

Read More
news image

CELL AND GENE THERAPY

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More
news image

OBSIDIAN THERAPEUTICS ANNOUNCES BRISTOL MYERS SQUIBB OPT-IN OF CYTODRIVE™ CELL THERAPY CANDIDATE

Obsidian Therapeutics | September 16, 2020

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop nov...

Read More
news image

ENTERPRISE THERAPEUTICS NABS NOVARTIS VC EXEC AS NEW CMO

FierceBiotech | February 10, 2020

Britain-based biotech Enterprise Therapeutics has hired Novartis Venture Fund managing director David Morris, M.D., as its next chief medical officer. Morris, who will continue to serve as the fund’s operating partner, will lead Enterprise’s development strategy and drive its two lead respiratory programs through the clinic. These are ETD002, a first-in-class TMEM16A potentiator, and ETD001, an ENaC blocker, both of which are hoping to help cystic fibrosis (CF) patients....

Read More